CP-037 Use of sofosbuvir in hepatitis C

Abstract

BackgroundHepatitis C is a serious disease with a high prevalence, being the leading cause of liver transplantation. There is now rapid development of new drugs for this disease. During the period of this study, only the following anti-hepatitis C agents were available: peg-interferon, telaprevir, boceprevir, simeprevir, sofosbuvir daclatasvir and ribavirin.PurposeTo analyse the effectiveness of sofosbuvir associated with other antiviral against hepatitis C, and identify adverse reactions produced.Material and methodsA descriptive study including patients that started therapy with sofosbuvir from August 2014 to January 2015. Data collected were: viral genotype, treatment duration with sofosbuvir and negativisation time to viral load.ResultsDuring the study period, 37 patients began treatment with sofosbuvir. Of these, 28 had genotype 1b (17 were treated for 12 weeks and 11 during 24 weeks), 3 had genotype 1a, 2 had genotype 3 and 4 had genotype 4. Patients with genotypes 1a and 4 were treated for 12 weeks and those with genotype 3 for 24 weeks.With respect to treatment for 12 weeks, the associations used most were sofosbuvir with simeprevir and ribavirin in 65.22% of patients. This was also the most prescribed combination in patients with genotype 1b, being used in 11.45.5%. Genotype 1b patients treated with this combination had a rapid virological response (RVR), which means an undetectable viral load in week 4 of treatment.In the 24 week treatment, 76.92% of patients (10 patients) received sofosbuvir with daclatasvir. Of these patients, 9 had genotype 1b. 55.5% of patients with genotype 1b and the above combination had a RVR.37 patients had undetectable viral load at the end of treatment. All patients achieved a sustained viral response at 4 weeks post-treatment (SVR4), and also showed a sustained viral response at 12 weeks post-treatment (SVR12), which means cure.ConclusionIn our patient population, using sofosbuvir associated with other antihepatitis C drugs available at the time of the study, helped to reduce the time required to neutralise the viral load, and present a good safety profile, which can improve adhesion.References and/or AcknowledgementsGutierrez JA, Lawitz EJ, Poordad F. Interferon-free, direct-acting antiviral therapy for chronic hepatitis. J Viral Hepat 2015No conflict of interest.